Brainsway Ltd
$ 24.41
1.20%
24 Feb - close price
- Market Cap 493,168,000 USD
- Current Price $ 24.41
- High / Low $ 24.73 / 23.90
- Stock P/E 76.28
- Book Value 1.79
- EPS 0.32
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.11 %
- 52 Week High 26.63
- 52 Week Low 7.84
About
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Analyst Target Price
$26.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-11 | 2025-08-13 | 2025-05-06 | 2025-03-04 | 2024-11-13 | 2024-08-06 | 2024-05-08 | 2024-03-06 | 2023-11-15 | 2023-08-09 | 2023-05-17 | 2023-03-15 |
| Reported EPS | 0.04 | 0.05 | 0.02 | 0.04 | 0.02 | 0.04 | 0.0067 | 0.0076 | -0.02 | -0.1 | -0.14 | -0.24 |
| Estimated EPS | 0.05 | 0.03 | 0.0233 | 0.02 | 0.01 | -0.01 | -0.02 | -0.01 | -0.03 | -0.09 | -0.1 | -0.13 |
| Surprise | -0.01 | 0.02 | -0.0033 | 0.02 | 0.01 | 0.05 | 0.0267 | 0.0176 | 0.01 | -0.01 | -0.04 | -0.11 |
| Surprise Percentage | -20% | 66.6667% | -14.1631% | 100% | 100% | 500% | 133.5% | 176% | 33.3333% | -11.1111% | -40% | -84.6154% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.11 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BWAY
2026-02-23 13:17:13
BrainsWay Ltd. announced its management will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day in New York, NY on February 26, 2026. The company, a leader in Deep Transcranial Magnetic Stimulation (Deep TMS™) for mental health disorders, aims to engage with investors and expand awareness of its FDA-cleared neurostimulation treatments. BrainsWay is recognized for its scientifically backed solutions for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
2026-02-23 12:52:41
BrainsWay Ltd. (NASDAQ & TASE: BWAY) announced its management will participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day on February 26, 2026, in New York, NY, for one-on-one meetings. The company is a global leader in advanced noninvasive brain stimulation technologies, specifically its Deep Transcranial Magnetic Stimulation (Deep TMS™) platform, which has three FDA-cleared indications for mental health disorders. BrainsWay is inviting interested parties to contact their Citi representative to request a meeting at the conference.
2026-02-20 09:10:16
BrainsWay's stock gained after Cigna announced it would remove prior authorization requirements for transcranial magnetic stimulation (TMS) therapy for depression, effective March 15, 2026. This change is expected to increase access to BrainsWay's Deep TMS therapy, potentially boosting its utilization and revenue. The move aligns with efforts to reduce barriers to mental health treatments.
2026-02-20 04:57:29
BrainsWay (NASDAQ: BWAY) saw its shares rise by 4.2% after Cigna announced the removal of prior authorization requirements for transcranial magnetic stimulation (TMS) therapy for depression. This policy change, effective in April 2026, simplifies patient access to BrainsWay's Deep TMS system, potentially boosting adoption and revenue. The move reflects increasing acceptance of TMS as a frontline treatment for depression.
2026-02-19 21:00:21
BrainsWay has announced a new minority-stake investment in BrainStim Health Inc., a Canadian mental health provider, with an initial investment of $1.0 million and potential for an additional $1.5 million. This is BrainsWay's fifth such investment, aiming to expand access to its Deep TMS technology. BrainStim's Chief Medical Officer, Dr. Venu Karapeddy, expressed enthusiasm for the partnership, which is expected to accelerate BrainStim's growth and delivery of mental health care.
2026-02-19 12:57:19
BrainsWay has invested $1.0 million, with a potential additional $1.5 million, for a minority stake in BrainStim Health Inc., a Canadian mental health provider. This marks BrainsWay's fifth such investment, aiming to expand access and awareness of its Deep TMS technology while focusing on scientific advancements. BrainStim's Chief Medical Officer, Dr. Venu Karapeddy, expressed enthusiasm for the partnership, expecting it to strengthen their offerings and accelerate growth in delivering mental health care.
